Athenex Announces Appointment of Jordan S. Kanfer to Board of Directors
“Jordan will be a tremendous asset to our Board. As an experienced global fund manager and life sciences investor he has a broad understanding of the investment community and global healthcare market,” said Dr.
Mr. Kanfer stated, “I am honored to join the Board of Directors for
“We thank SongYi for his tremendous guidance, generosity and commitment during his tenure as a board member. As an early investor in
Mr. Zhang commented, “I have great respect for
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on non-absorbed P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments.
Managing Director, LifeSci Advisors, LLC
Tel: +1 716-427-2952
Direct: +1 212-915-2564